Literature DB >> 28867623

Colonization, resistance to bile, and virulence properties of Escherichia coli strains: Unusual characteristics associated with biliary tract diseases.

Maryam Razaghi1, Elahe Tajeddin1, Leila Ganji2, Masoud Alebouyeh3, Amir Houshang Mohammad Alizadeh4, Amir Sadeghi5, Mohammad Reza Zali6.   

Abstract

Escherichia coli is the species that is most frequently isolated from bile of patients with biliary tract diseases. This study was aimed to investigate any association between resistance and virulence properties of these isolates with occurrence of the diseases. A total of 102 bile samples were obtained from patients subjected to endoscopic retrograde cholangiopancreatography for different biliary diseases. Clinical data were collected and culture of the bile samples was done on selective media. Resistance of characterized Escherichia coli isolates to deoxycholate sodium (0-7%) and nineteen antibiotics was determined and PCR using 16 pairs of primers targeting stx1, stx2, exhA, eae, bfp, agg, pcvd432, lt, st, ipaH, pic, pet, ast, set, sen, and cdtB genes was done. Our results showed a statistically significant association between E. coli colonization and existence of common bile duct and gallbladder stones (p value 0.028). Out of the 22 E. coli strains (22/102) multidrug resistance phenotype was present in 95.45%. None of the strains belonged to common E. coli pathotypes. However, bfp + EhxA-hly, bfp + astA, bfp + EhxA-hly + pic, and EhxA-hly + pic + astA, bfp, and astA genotypes were detected in these strains. bfp (7/22, 31.8%) and astA (5/22, 22.7%) were among most frequent virulence factors in these strains. Results of this study showed significant association between colonization of E. coli and choledocholithiasis. Unusual existence of virulence gene combinations in these strains and their resistance to DOC and multiple classes of antibiotics could be considered as possible causes of their persistence in this harsh microenvironment.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biliary tract infection; Endoscopic retrograde cholangiopancreatography; Escherichia coli; Multiple drug resistance; Virulence

Mesh:

Substances:

Year:  2017        PMID: 28867623     DOI: 10.1016/j.micpath.2017.08.043

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  5 in total

Review 1.  The Great ESKAPE: Exploring the Crossroads of Bile and Antibiotic Resistance in Bacterial Pathogens.

Authors:  Kevin S Gipson; Kourtney P Nickerson; Eliana Drenkard; Alejandro Llanos-Chea; Snaha Krishna Dogiparthi; Bernard B Lanter; Rhianna M Hibbler; Lael M Yonker; Bryan P Hurley; Christina S Faherty
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

2.  Microbiota analysis with next-generation 16S rDNA gene sequencing in recurrent common bile duct stones.

Authors:  Wenhui Tan; Ruiyan Chen; Jie Song; Donghong He; Jiachuan Wu; Xiaodong Chen; Xiaoqiao Yang; Lifang Ye
Journal:  Ann Transl Med       Date:  2022-05

3.  Phylogeny, Resistome, and Virulome of Escherichia coli Causing Biliary Tract Infections.

Authors:  Ángel Rodríguez-Villodres; Rémy A Bonnin; José Manuel Ortiz de la Rosa; Rocío Álvarez-Marín; Thierry Naas; Javier Aznar; Jerónimo Pachón; José Antonio Lepe; Younes Smani
Journal:  J Clin Med       Date:  2019-12-02       Impact factor: 4.241

4.  Alterations of the Bile Microbiome in Recurrent Common Bile Duct Stone.

Authors:  Cheng Ye; Wence Zhou; Hui Zhang; Long Miao; Gen Lv
Journal:  Biomed Res Int       Date:  2020-09-29       Impact factor: 3.411

5.  Serum procalcitonin levels associate with Clostridioides difficile infection in patients with inflammatory bowel disease.

Authors:  Mohammad Abdehagh; Masoumeh Azimirad; Hamidreza Houri; Banafsheh Nadalian; Fahimeh Azimirad; Meysam Olfatifar; Ome Kolsoum Nasir Shoeibi; Abbas Yadegar; Shabnam Shahrokh; Mehran Mahdavi Roshan; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  BMC Infect Dis       Date:  2021-10-26       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.